Literature DB >> 14987351

Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia.

Roberta L Keller1, Shannon E G Hamrick, Joseph A Kitterman, Jeffrey R Fineman, Samuel Hawgood.   

Abstract

OBJECTIVE: We describe a case of chronic pulmonary hypertension in a 7-wk-old infant with congenital diaphragmatic hernia and an oral teratoma. Our patient was dependent on low-dose inhaled nitric oxide and was still very unstable with systemic right ventricular pressures leading to frequent oxygen desaturations. We administered sildenafil therapy to stabilize the infant with discontinuation of inhaled nitric oxide. We describe successful discontinuation of the inhaled therapy as well as a period of stabilization and improvement with continued sildenafil administration.
DESIGN: Case report.
SETTING: Intensive care nursery in tertiary academic center. PATIENT: A 7-wk-old infant with congenital diaphragmatic hernia who was mechanically ventilated from birth. INTERVENTION: Oral sildenafil 0.3 mg/kg/dose every 12 hrs. MEASUREMENTS AND
RESULTS: Right ventricular pressure (from tricuspid valve regurgitant flow) to systemic systolic arterial pressure was measured by echocardiogram. Right ventricular to systemic pressure ratio was marginally improved with the initiation of sildenafil therapy. Inhaled nitric oxide was successfully discontinued, and the patient clinically stabilized temporarily, but he ultimately succumbed to his pulmonary hypertension.
CONCLUSION: Sildenafil may be a useful therapy for chronic pulmonary hypertension in congenital diaphragmatic hernia, but further studies of safety and efficacy need to be performed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14987351     DOI: 10.1097/01.pcc.0000113266.26638.ad

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  5 in total

1.  Effect of a phosphodiesterase 5 inhibitor on pulmonary and cerebral arteries of newborn piglets with chronic hypoxia-induced pulmonary hypertension.

Authors:  Candice D Fike; Mark Kaplowitz; Yongmei Zhang; Mark Dantuma; Jane A Madden
Journal:  Neonatology       Date:  2011-07-26       Impact factor: 4.035

Review 2.  Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension.

Authors:  Kathryn N Farrow; Robin H Steinhorn
Journal:  Handb Exp Pharmacol       Date:  2011

Review 3.  Sildenafil for the treatment of pulmonary hypertension in pediatric patients.

Authors:  Alice J Huddleston; Chad A Knoderer; Jennifer L Morris; Eric S Ebenroth
Journal:  Pediatr Cardiol       Date:  2009-08-25       Impact factor: 1.655

Review 4.  Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.

Authors:  Satyan Lakshminrusimha; Bobby Mathew; Corinne L Leach
Journal:  Semin Perinatol       Date:  2016-01-14       Impact factor: 3.300

5.  Sildenafil attenuates hepatocellular injury after liver ischemia reperfusion in rats: a preliminary study.

Authors:  Spyridon Savvanis; Constantinos Nastos; Marios-Konstantinos Tasoulis; Nikolaos Papoutsidakis; Maria Demonakou; Iosifina Karmaniolou; Nikolaos Arkadopoulos; Vassilios Smyrniotis; Kassiani Theodoraki
Journal:  Oxid Med Cell Longev       Date:  2014-06-04       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.